Prospective Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Jan 14, 2022; 28(2): 263-274
Published online Jan 14, 2022. doi: 10.3748/wjg.v28.i2.263
Table 1 Baseline characteristics of hepatitis C virus-infected patients receiving directly-acting antivirals therapy between sporadic hepatitis C virus therapy in outpatient clinics and campaign of hepatitis C virus micro-elimination in Penghu prison
TotalSporadic HCV therapy in outpatient clinics (January 1, 2019 - December 31, 2019)Campaign of HCV micro-elimination (January 1, 2020 - March 31, 2020)P value
n30391212-
Age (yr)48.4 ± 8.247.6 ± 8.748.7 ± 8.00.271
Male303 (99.7)90 (98.9)212 (100.0)0.126
1BMI, kg/m223.9 ± 3.223.9 ± 3.323.9 ± 3.20.986
> 27 kg/m234 (13.8)11 (13.9)23 (13.4)0.960
Diabetes10 (3.3)8 (8.8)2 (0.9)0.0005a
Hypertension59 (19.5)25 (27.5)34 (16.0)0.021a
Hyperlipidemia8 (2.6)7 (7.7)1 (0.5)0.0003a
Cardiovascular disease2 (0.7)1 (1.1)1 (0.5)0.537
HBsAg (+)30 (9.9)9 (9.9)21 (9.9)0.997
AST, IU/L41.3 ± 35.545.9 ± 38.939.4 ± 33.80.168
ALT, IU/L65.4 ± 77.471.6 ± 69.862.7 ± 80.40.329
Abnormal AST or ALT159 (52.5)54 (59.3)105 (49.5)0.117
White cell count, × 103/ìL6.6 ± 1.96.4 ± 2.06.7 ± 1.80.188
Hemoglobin concentration, g/dL15.9 ± 1.316.0 ± 1.315.9 ± 1.30.762
Platelet count, × 103u/L227.6 ± 67.4219.4 ± 72.1231.2 ± 65.10.181
Albumin, g/dl4.5 ± 0.34.5 ± 0.44.5 ± 0.20.233
Total bilirubin, mg/dL0.8 ± 0.30.9 ± 0.40.8 ± 0.30.003a
LC1 (0.3)1 (1.1)0 (0.0)0.300
FIB-41.3 ± 1.01.5 ± 1.41.2 ± 0.80.096
> 3.2520 (6.6)10 (11.0)10 (4.7)0.044a
eGFR, mL/min/1.73 m299.9 ± 17.799.1 ± 21.0100.3 ± 16.40.624
< 604 (1.3)3 (3.3)1 (0.4)0.048a
HCV RNA, log10 IU/mL6.5 ± 1.16.0 ± 1.06.7 ± 1.1< 0.001a
HCV genotype, 1/2/1+2/3/6128 (42.2)/32 (10.6)/1 (0.3)/35 (11.6)/107 (35.3)38 (41.8)/9 (9.9)/0/11 (12.1)/33 (36.2)90 (42.5)/23 (10.8)/1 (0.5)/24 (11.3)/74 (34.9)0.968
DAA regimen
SOF/VEL212 (70.0)0 (0.0)212 (100.0)< 0.001a
SOF/LDV78 (25.7)78 (85.7)0 (0.0)
GLE/PIB13 (4.3)13 (14.3)0 (0.0)
Prior treatment history
Naïve300 (99.0)89 (97.8)211 (99.5)0.216
Experienced-IFN3 (1.0)2 (2.2)1 (0.5)
Table 2 Virological responses of hepatitis C virus-infected patients receiving directly-acting antivirals therapy before and during campaign of hepatitis C virus micro-elimination in Penghu prison in Penghu prison
Undetectable HCV RNA, n/N (%)TotalSporadic HCV therapy in outpatient clinics (January 1, 2019 - December 31, 2019)Campaign of HCV micro-elimination with simplified pan-genotypic SOF/VEL regimen (January 1, 2020 - March 31, 2020)P value
Intention-to-treat population
Treatment 4 wk284/303 (93.7)85/91 (93.4)199/212 (93.9)0.879
End-of-treatment 300/303 (99.0)91/91 (100.0)209/212 (98.6)0.557
End-of 12 wk follow-up289/303 (95.4)86/91 (94.5)203/212 (95.8)0.126
Per-protocol population
Treatment 4 wk284/301 (94.4)85/901 (94.4)199/2112 (94.3)0.964
End-of-treatment 300/300 (100.0)91/91 (100.0)209/2093 (100.0)-
End-of 12 wk follow-up289/290 (99.7)86/874 (98.9)e5203/2036 (100.0)0.126
Table 3 Safety profiles of hepatitis C virus-infected patients receiving direct-acting antivirals therapy in Penghu prison
n (%)
Total
Sporadic HCV therapy in outpatient clinics (January 1, 2019 - December 31, 2019)
Campaign of HCV micro-elimination with simplified pan-genotypic SOF/VEL regimen (January 1, 2020 - March 31, 2020)
n30391212
Treatment discontinuation other than released or transferred 0 (0.0)0 (0.0)0 (0.0)
Serious adverse events 0 (0.0)0 (0.0)0 (0.0)
Death 0 (0.0)0 (0.0)0 (0.0)
Adverse events 7 (2.3)4 (4.3)3 (1.4)
Fatigue0 (0.0)0 (0.0)0 (0.0)
Pruritus 2 (0.7)0 (0.0)2 (0.9)
Rash3 (1.0)3 (3.2)0 (0.0)
Nausea 0 (0.0)0 (0.0)0 (0.0)
Anorexia 0 (0.0)0 (0.0)0 (0.0)
Constipation0 (0.0)0 (0.0)0 (0.0)
Dizziness0 (0.0)0 (0.0)0 (0.0)
Insomnia0 (0.0)0 (0.0)0 (0.0)
Headache1 (0.3)0 (0.0)1 (0.5)
Others1 (0.3)1 (1.0)0 (0.0)
Grade 3 or 4 laboratory abnormalities
Total blood bilirubin0 (0.0)0 (0.0)0 (0.0)
Alanine aminotransferase0 (0.0)0 (0.0)0 (0.0)

  • Citation: Chen CT, Lu MY, Hsieh MH, Tsai PC, Hsieh TY, Yeh ML, Huang CI, Tsai YS, Ko YM, Lin CC, Chen KY, Wei YJ, Hsu PY, Hsu CT, Jang TY, Liu TW, Liang PC, Hsieh MY, Lin ZY, Huang CF, Huang JF, Dai CY, Chuang WL, Shih YL, Yu ML. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. World J Gastroenterol 2022; 28(2): 263-274
  • URL: https://www.wjgnet.com/1007-9327/full/v28/i2/263.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v28.i2.263